INTRODUCTION
SGB-017, also known as (+)ADCI, NGB-812 or WAY-143017, is a novel anticonvulsant with two known mechanisms of action. It inhibits N-methyl-d-aspartate (NMDA) receptor channels in a noncompetitive and use-dependent manner (13, 24) , and like many standard anticonvulsants (i.e., carbamazepine, phenytoin, and lamotrigine), SGB-017 also blocks sodium channels in a voltage-dependent manner (28, 31) . The dual action of blocking both NMDA as well as sodium channels, suggests that SGB-017 may be useful in treating some epilepsies that are resistant to carbamazepine or phenytoin treatment.
In the anticonvulsant-screening program at the Epilepsy Research Branch, National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Health (NIH), SGB-017 was found to be a moderately potent anticonvulsant with a good margin of safety. Like carbamazepine, SGB-017 was effective in preventing seizures induced by maximal electroshock (MES) and by potassium channel blockers, such as dendrotoxin or 4-aminopyridine, but was ineffective against pentylenetetrazol-, bicuculline-, or strychnine-induced seizures (5, 24, 34) . Unlike carbamazepine, it also prevented seizures induced by ethanol withdrawal, cocaine, or NMDA, and retarded the onset of kindled seizures (12, 24, 27) . The latter types of seizures are typically unresponsive to sodium channel blockers, but can be inhibited by NMDA antagonists, such as dizocilpine (MK-801).
Although it acts at the same site as MK-801 and phencyclidine (PCP), SGB-017 does not have any of the liabilities associated with NMDA antagonists in animal models, such as psychotomimetic effects, deficits in cognition, or neurotoxicity (14, 20) . It does not substitute for MK-801 in rats trained to discriminate between MK-801 and saline (11) . In various rat behavioral models, SGB-017 produced neither deficits in learning and memory nor vacuolizations or lesions in the brain, which are typically associated with NMDA an-tagonists. Ataxia and other motor deficits were observed only with high doses of SGB-017.
CHEMISTRY
SGB-017 is the (+) and more potent enantiomer of (±)-(5R,10S )-aminocarbonyl-5H-dibenzo-a,d-cycloheptan-5,10-imine (ADCI). As a tartrate salt, it is a white crystalline solid with a molecular weight of 401.5 daltons (C 20 H 22 N 2 O 7 ) and has the following chemical structure:
PHARMACOLOGY SGB-017 is chemically related to MK-801 and carbamazepine, and it has similar pharmacological properties. Like MK-801, it is a noncompetitive and use-dependent blocker of NMDA receptor channels, but with a much lower affinity. Like carbamazepine, SGB-017 is a use-and voltage-dependent blocker of sodium channels. The combination of NMDA receptor and sodium channel blocking activities indicate that SGB-017 may be an effective anticonvulsant and prove to be a useful therapy for the forms of epilepsy that are unresponsive to currently available anticonvulsants.
In Vitro Studies

Block of NMDA receptor currents
Glutamate is the main excitatory neurotransmitter in the brain. It activates at least three receptor subtypes named for their specific agonists: NMDA, AMPA/kainate, and quisqualate (19, 26) . Normal excitatory synaptic transmission between neurons requires the activation of AMPA/kainate receptors that allow sodium ions to enter and depolarize the neuron. Activation of NMDA receptors, which allows calcium as well as sodium ions to permeate the neuron, is necessary for learning and memory (1, 6, 7, 17) . However, overstimulation of glutamate receptors can produce an uncontrolled influx of calcium, resulting in prolonged membrane depolarization and neuronal cell death (4, 9) .
The effects of SGB-017 on NMDA-induced currents were examined in cultured hippocampal neurons (13, 24) . By itself, concentrations of SGB-017 up to 1 mM had no effect on the holding current in hippocampal neurons, which were voltage clamped at -60 mV.
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However, when it was concomitantly applied with 30 µM NMDA, SGB-017 reduced the NMDA-induced current. The block of NMDA-induced current during the first concomitant application of SGB-017 and NMDA was small, but it increased with repetitive concomitant applications of SGB-017 and NMDA until a steady state level of inhibition was achieved (Fig. 1A ) (12) . Like MK-801 and PCP, SGB-017 binds at a site in the NMDA receptor channel pore and blocks the influx of calcium and sodium ions. It can enter the channel only when the channel is open following the binding of glutamate or NMDA to the receptor. The longer the channel is open, the more likely it is to be blocked by SGB-017. The IC 50 for steady state inhibition of NMDA-induced currents by SGB-017 is 14 µM (13, 24) . With 100 µM NMDA, the IC 50 increases only slightly to 15.6 µM (Fig. 1B) . These features are characteristic of a noncompetitive, use-dependent blocker. Similar block of NMDA-induced currents occurs with MK-801, which has an IC 50 of 20 nM (13) . In contrast, 300 µM carbamazepine has little effect on NMDA-induced currents (24) . The block of NMDA-induced currents by SGB-017 is also voltage-dependent. At a holding potential of -60 mV, 300 µM SGB-017 inhibited most NMDA-induced currents, but at a holding potential of +40 mV, the same concentration of SGB-017 inhibited only 40-50% of the NMDA-induced currents. At positive potentials, the net current flowing through the NMDA receptor channel is outward. Thus, SGB-017 may be knocked off its binding site in the NMDA receptor channel by outward currents in a manner similar to other ion channel pore blockers (16) . These effects were specific to the NMDA glutamate receptor subtype, since 100 µM SGB-017 had no effect on glutamate-receptor currents activated by 5 µM quisqualate or 20 µM kainate (13) .
By blocking only NMDA glutamate receptors in a use-dependent manner, SGB-017 is predicted to have little effect on normal synaptic transmission, learning, and memory. However, under conditions of neuronal excitation when NMDA receptors are activated for prolonged periods, SGB-017 produces its greatest inhibition of NMDA-induced currents to prevent seizure activity.
Block of sodium channel currents
The actions of SGB-017 on sodium channels resemble that of carbamazepine; they are both reversible, voltage-dependent blockers of sodium channels (28, 31) . The potency of inhibition with either drug is highly sensitive to the holding potential. Both drugs have little effect on sodium currents elicited from neurons with a holding potential of -100 mV. At more depolarized potentials, the potency of both drugs increases. IC 50 s for the inhibitory action of SGB-017 at sodium channels in rat hippocampal neurons, held at -80 and -60 mV holding potentials, are 144 and 24 µM, respectively (Fig. 2) . These are similar to the IC 50 s for carbamazepine, which are 120 and 18 µM at the same respective holding potentials. Maintaining the membrane potential at a less negative voltage is known to increase the proportion of sodium channels in the slow inactivated state (3, 25, 33) . This voltage-dependency suggests that SGB-017 has a much higher affinity for the inactivated state of the sodium channel compared to the resting state. SGB-017 exerts its anticonvulsant action when the sodium channel develops slow inactivation, which occurs during a large or prolonged depolarization and under a repetitive firing condition, such as during seizures. Since sodium channels in peripheral neurons differ from those in the CNS (30), the effects of SGB-017 on sodium currents in rat sympathetic and hippocampal neurons were compared. IC 50 s for the inhibitory action of SGB-017 at sodium channels in sympathetic neurons held at -80 and -60 mV are 209 and 60 µM, respectively (28) . Thus, like carbamazepine, SGB-017 blocked sodium channels in hippocampal neurons more potently than in sympathetic neurons.
CNS
The affinity of SGB-017 for human sodium channels in NT2 neurons has also been determined (21). IC 50 s for SGB-017 inhibition of sodium currents in NT2 neurons at holding potentials of -80 and -60 mV are 335 and 23 µM, respectively. These are slightly less than those for carbamazepine (561 and 50 µM, respectively) (28). These results indicate that SGB-017 should be at least as efficacious as carbamazepine in preventing seizures in humans, and it should have minimal peripheral side effects.
Other activity
To determine if SGB-017 has any additional mechanisms of action, this agent was screened in 84 receptor, ion channel, second messenger, and enzyme binding assays (Wyeth-Ayerst Laboratories Internal Report). At a concentration of 10 mM, SGB-017 did not inhibit the binding of any ligand by more than 50%. It had the highest affinity at the NMDA receptor channel pore, inhibiting binding at MK-801 and TCP sites (TCP:
-piperidine) by 42 and 41%, respectively. SGB-017 had no effect on glutamate or glycine binding. At 100 µM, SGB-017 reduced binding at MK-801 and TCP sites by 102 and 98%, respectively. At this concentration, it also inhibited binding of pirenzepine to muscarinic M 1 receptors by 95%, LSD to nonselective serotonin binding sites by 74%, batrachotoxin to sodium channels by 64%, promogestone to progesterone receptors by 61%, diltiazem to L-type calcium channels by 58%, and charybdotoxin to calcium-activated potassium channels by 55% (Table 1 ).
In Vivo Studies
Animal models of epilepsy SGB-017 was tested by the Epilepsy Research Branch at NINDS, NIH and found to be effective in a number of animal models of epilepsy (5, 24, 34) . These include the inhibition of seizures induced by MES, kainate, NMDA, and the potassium channel blockers 4-AP and dendrotoxin. The efficacy of SGB-017 and other drugs in these and other models of epilepsy are compared in Table 2 . In all of these studies, ADCI, which is a mixture of SGB-017 and its (-) enantiomer, was used. ADCI was effective also in retarding the development of kindling in rats and preventing seizures induced by ethanol withdrawal or cocaine injection in mice (12, 24, 27) . At a dose of 18 mg/kg i.p., ADCI (MW = 251.5, free acid) increased the number of days required to produce an after-discharge (from 2.5 to 6.8 d) and achieve stage 5 seizures (from 9.7 to 13.8 d) in amygdaloid-kindled rats. There was no effect on the after-discharge duration (control = 76.3 s and ADCI = 72.5 s). ADCI at 3 and 10 mg/kg reduced the severity and duration of seizures occurring in mice following withdrawal from ethanol. This reduction was similar to that seen with 0. In addition to its efficacy in a number of epilepsy models, SGB-017 has a relatively large margin of safety. Its therapeutic index, defined as the TD 50 in the motor toxicity test divided by the ED 50 in the MES test, was 5.5 in mice and > 138 in rats. These are comparable to the therapeutic indices of carbamazepine and phenytoin and greater than the therapeutic indices for dizocilpine and valproate.
Tolerance
Chronic treatment with carbamazepine causes blood levels to decrease due to enhanced metabolism of the drug (2). This type of tolerance can be overcome by increasing the carbamazepine dose (18) . Other forms of tolerance, such as those induced by chronic treatment with benzodiazepines, do not result in decreased blood levels. Instead, they are due to decreased sensitivity to drug (10, 15) , which cannot be overcome by increasing the drug dose.
Chronic treatment with SGB-017 also induces tolerance to the drug (23). After 1 or 2 weeks (w) of three times daily injections of 18 mg/kg ADCI (twice the ED 50 for MES), only 10 of 35 (29%, 1 w) and 0 of 31 (0%, 2 w) mice were protected against MES with an CNS Drug Reviews, Vol. 5, No. 4, 1999 SGB-017 373 There was no change in the binding of [ 3 H]dizocilpine to brains in mice treated with ADCI for 2 w compared to control. This indicated that chronic treatment with ADCI did not decrease the number of NMDA receptors in rat brain and thus the sensitivity to the drug. Following a single injection dose of 18 mg/kg, the mean plasma level of ADCI in drug-naive animals was 5.5 µg/mL compared to 4.2 µg/mL in mice treated with ADCI for 1 w. After 2 w, mean plasma ADCI levels were 6.5 µg/mL for naive and 3.5 µg/mL for ADCI treated mice (23) . Therefore, as with carbamazepine, chronic treatment with ADCI enhances metabolism of the drug and results in reduced plasma levels, which decreases the ability of a given dose of ADCI to protect against MES-induced seizures. Chronically treated mice could be protected against MES-induced seizures with injections of higher doses of ADCI. The ADCI MES ED 50 for chronically treated animals was 28.9 mg/kg. Mean plasma concentration following this dose was 7.0 µg/mL.
Drug discrimination
MK-801 produces a variety of adverse neurobehavioral effects in animals and humans which limit its usefulness as a neuroprotective and anticonvulsive agent (14, 32) . To determine whether SGB-017 might have similar adverse neurobehavioral effects, drug discrimination studies were conducted with ADCI on rats trained to discriminate MK-801 from saline administered i.p. (11) . In these rats, 3.0-5.6 mg/kg phencyclidine or 10-56 mg/kg ketamine completely substituted for 0.03-0.3 mg/kg MK-801 without any change in the rat response rate. By contrast, there was no substitution with 30-78 mg/kg ADCI i.p.
Vacuolization
MK-801 and many other NMDA antagonists are known to cause vacuolization and lesions in the posterior cingulate and retrosplenial cortices of adult rat brains (20) . Vacuolization in the cingulate and retrosplenial regions has been suggested to be correlated with psychotic symptoms induced by NMDA antagonists. Olney and colleagues tested SGB-017 and found no evidence of vacuolization in 12 rats that were examined 6 h after treatment with 200 mg/kg SGB-017 tartrate administered by oral gavage (8) . At this dose, animals were somnolent and remained so for at least 12 h. In another 12 rats, no lesions were found in any section of the rat brain at 72 h following the administration of 200 mg/kg SGB-017 tartrate. For comparison, the ED 50 for SGB-017 administered p.o. in the rat MES test was 13.2 mg/kg (active moiety). In toxicity studies, chronic oral dosing of SGB-017 tartrate at the high dose of 300 mg/kg per day was lethal to rats. In contrast, a dose of 5 mg/kg MK-801 produced vacuolization in both the left and right sides of the cingulate/retrosplenial cortex in all five animals examined at 6 h after injection. In other rats examined at 72 h after MK-801 administration, all four rats had necrotic neurons in both sides of the brain. All animals were hyperactive and ataxic shortly after injection of CNS Drug Reviews, Vol. 5, No. 4, 1999 374
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MK-801, and those surviving for 72 h required hand feeding and periodic saline injections to maintain nutrition and hydration.
Learning and memory
NMDA receptors are known to play an important role in learning and memory (6, 7, 17) . Thus, drugs that inhibit NMDA receptors may adversely affect learning. To determine its effects on learning and memory, SGB-017 was tested in a number of behavioral and learning paradigms (8, 22) . These included locomotor activity, step down passive avoidance, and Morris water maze tests. The effects of SGB-017 were compared to those of carbamazepine, MK-801, phenytoin, phenobarbital, and valproic acid in all three tests. SGB-017, carbamazepine, phenytoin, and phenobarbital were tested at 3 and 10 times the MES ED 50 . Due to severe motor impairments at higher doses, MK-801 was tested at 1, 2, and 4 times the MES ED 50 and valproate was tested at 0.5, 1, and 3 times the MES ED 50 . All drugs were administered by oral gavage in a 0.5% carboxymethylcellulose suspension prior to the initiation of the task.
In the locomotor activity test, the total distance an animal traveled in a 15-minute period was recorded. SGB-017 (23 and 77 mg/kg) and phenytoin (70 and 230 mg/kg) had no significant effect on locomotor activity. Carbamazepine (10 and 35 mg/kg), phenobarbital (30 and 105 mg/kg) and valproate (395 and 1185 mg/kg, 1 and 3 times MES ED 50 , respectively) significantly decreased the distance traveled from 2000 cm to less than 1500 cm (P < 0.05). MK-801 at 1 mg/kg (MES ED 50 ) significantly increased the total distance traveled from 2000 cm to > 6000 cm. Thus, SGB-017 neither produces sedation like carbamazepine, phenobarbital, and valproate nor does it act as a stimulant like MK-801.
The step down passive avoidance task assesses both acquisition and memory components of learning. One advantage of this task is that the memory component (retention testing) is conducted in a drug-free state. Animals were placed on a platform raised above a shock grid floor inside a test chamber. Each time the animal stepped down from the platform it received a shock. The animal was placed back on the platform if it did not respond within a defined time. The number of trials required until the animal remained on the platform for 120 s was recorded. Animals were tested for retention 24 h later. Each animal was placed back on the platform and the latency to stepping down onto the now unshocked floor was recorded. Animals were allowed 120 s to step down.
At 3 and 10 times the MES ED 50 , SGB-017, carbamazepine, and phenytoin produced no deficit in either acquisition or retention. At 0.5 and 1 times the MES ED 50 MK-801, 3 and 10 times the MES ED 50 phenobarbital, and 1 times the MES ED 50 valproate, the number of trials required in the acquisition period increased significantly from less than 10 to greater than 20 trials. The time to step down during the retention trial also decreased significantly from almost 40 seconds to less than 20 seconds. Therefore, these drugs adversely affect learning and memory.
The Morris water maze assesses spatial learning involving the hippocampal region of the brain. Animals were trained to find an unseen, submerged platform in a circular pool of cloudy water, using only visual cues in the area around the tank. One day after training, they were retested and the time required for the animal to find the platform were recorded. SGB-017 and carbamazepine produced no deficits in the Morris water maze task at 3 and 10 times the MES ED 50 . By contrast, MK-801 (0.5 mg/kg), phenytoin (230 mg/kg), phe-nobarbital (60 mg/kg), and valproate (395 mg/kg) significantly increased the time taken to find the platform from approximately 30 s to over 60 s.
Thus, at doses of 3 and 10 times the MES ED 50 , SGB-017 had no effects on locomotor activity or learning and memory in both the step down passive avoidance task and Morris water maze. Carbamazepine decreased locomotor activity and phenytoin increased the learning time in the Morris water maze. The remaining drugs: MK-801, phenobarbital, and valproic acid, produced deficits in all three tests.
CONCLUSION
Preclinical pharmacology studies provide evidence that SGB-017 will have a superior therapeutic ratio for efficacy relative to side effects. Like carbamazepine, SGB-017 blocks sodium channels in a voltage-and use-dependent manner, and it is effective in several animal models of epilepsy, including MES, and 4-AP-or dendrotoxin-induced seizures. Based on its lower IC 50 s to block human sodium channels, SGB-017 should be at least as effective as carbamazepine as an anticonvulsant. Due to its additional ability to block NMDA receptor channels, SGB-017 is also effective in models of epilepsy where carbamazepine is ineffective. These models include: retarding the development of kindling in rats and preventing seizures induced by NMDA, cocaine or ethanol withdrawal in mice. Thus, SGB-017 may be effective in treating seizures in patients who are unresponsive to carbamazepine.
In addition to its efficacy in these epilepsy models, SGB-017 has a relatively large margin of safety. Its therapeutic index (motor toxicity TD 50 /MES ED 50 ) is comparable to that of carbamazepine and phenytoin in mice, and greater than that for either drug in rats. SGB-017 does not produce sedation or stimulation of locomotor activity at doses up to 10 times its MES ED 50 . Finally, unlike many other NMDA antagonists, SGB-017 causes no impairments in learning or memory and does not produce vacuolization or lesions in rat brain.
